- Home
- INSM
INSM
Insmed Incorporated
as 10-29-2025 4:00pm EST
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 29.0B | IPO Year: | 2000 |
| Target Price: | $160.47 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $60.40 - $168.22 | Next Earning Date: | 10-30-2025 |
| Revenue: | $398,105,000 | Revenue Growth: | 21.15% |
| Revenue Growth (this year): | 32.08% | Revenue Growth (next year): | 125.86% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Sep 12 '25 | Sell | $146.08 | 76,520 | $11,129,927.45 | 42,619 | |
| SHAROKY MELVIN MD | INSM | Director | Sep 12 '25 | Sell | $145.39 | 10,000 | $1,453,900.00 | 262,675 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Sep 2 '25 | Sell | $143.65 | 186,648 | $26,941,272.29 | 117,726 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Sep 2 '25 | Sell | $143.60 | 24,272 | $3,492,377.99 | 54,902 | |
| SHAROKY MELVIN MD | INSM | N/A | Aug 20 '25 | Sell | $129.50 | 10,000 | $1,295,000.00 | 262,675 | |
| Adsett Roger | INSM | Chief Operating Officer | Aug 19 '25 | Sell | $127.85 | 25,000 | $3,189,585.95 | 105,637 | |
| Lewis William | INSM | Chair and CEO | Aug 18 '25 | Sell | $128.61 | 6,865 | $881,470.20 | 237,821 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Aug 14 '25 | Sell | $127.48 | 10,000 | $1,273,363.44 | 42,619 | |
| SHAROKY MELVIN MD | INSM | N/A | Aug 12 '25 | Sell | $121.58 | 10,000 | $1,215,800.00 | 262,675 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
UBS Adjusts Insmed Price Target to $194 From $140, Maintains Buy Rating
The Wall Street Journal
17 days ago
Why Biotech’s Rally Can Last This Time
Simply Wall St.
19 days ago
Insmed Insiders Sold US$36m Of Shares Suggesting Hesitancy
Simply Wall St.
25 days ago
How Analysts Are Rethinking Insmed After Brinsupri’s Approval and New Revenue Projections
Insider Monkey
a month ago
Ohio Retirement Fund Invests in Insmed Incorporated (INSM)
Zacks
a month ago
Is IPF the Next Big Market Opportunity for United Therapeutics?
Insider Monkey
a month ago
Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%
PR Newswire
a month ago
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.